The World Bank is failing miserably on malaria, like it failed on HIV/AIDS before.

The Global Fund is to be commended for its transparency, but it has failed to act on the information it has gleaned, and continues to allow its funds to be used by governmental distribution systems known to be corrupt.

In a new Lancet paper my colleagues and I point out that the World Bank has failed in its anti-malaria program. So what now?

The intent behind a proposed treaty to criminalize the manufacture and trade in counterfeited drugs is good, but only a treaty initiated by the World Health Organization will suffice.

There are always costs of both action and inaction; however, before a costly scheme is funded, better evidence of its effectiveness should be established.

The high persistence of substandard drugs and clinically inappropriate artemisinin monotherapies inAfrica risks patient safety and endangers the future of malaria treatment.

Fake drugs flourish in areas where government oversight is poor and private-sector accountability is weak, but failing to prevent counterfeit drug sales can have deadly consequences.

DDT is still a critical weapon in the battle against malaria and other insect-borne diseases.